Recently, our President and Managing Director, Jennifer Che, participated as a speaker at the HKSTP Market Discovery - BIO Connect event, hosted by HKSTP and InvestHK. This exclusive gathering brought together international biotech disruptors, offering them valuable insights into accessing the vast markets of Asia and beyond.

In her talk titled "Biotech Disruptors Benefit from HK IP," Jennifer highlighted the unique advantages Hong Kong offers from an intellectual property perspective. She discussed the rapidly developing IP ecosystem, including the homegrown original grant patent system and various tax and funding incentives that make the region an attractive hub for research and development. Additionally, she emphasized the expertise of local firms like Eagle IP, which are adept at navigating the complex IP challenges within the Greater Bay Area.

Our Past Events

Recommended Insights

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

14 July 2021
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

Can Post Filing Data Overcome Inventive Step in China?

19 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Top crossarrow-right